XDH and nephrolithiasis: UA is derived exclusively from the oxidation of xanthine and hypoxanthine by XOR[1], and pharmacological inhibition of XOR has been used extensively for the management of hyperuricemic disorders such as gout, nephrolithiasis, some cases of acute and chronic kidney disease, ischemia-reperfusion disorders, and others[2,3].